NEWARK, DE —The global antibiotics active pharmaceutical ingredient (API) market is projected to reach USD 9,100 million in 2026 and expand to USD 12,000 million by 2036, registering a steady CAGR of 2.8% over the forecast period. This sustained expansion reflects the ongoing need for reliable antibiotic production amid rising bacterial infection prevalence, growing demand for...

The global coronary stents market is set for steady expansion, rising from USD 37.5 billion in 2026 to USD 64.6 billion by 2036, reflecting a compound annual growth rate (CAGR) of 5.6%. Future Market Insights highlights that this trajectory is driven by the enduring worldwide prevalence of coronary artery disease and ongoing improvements in percutaneous coronary intervention (PCI)...

NEWARK, DE | The gynecological examination chairs market was valued at USD 697.7 million in 2025 and is estimated to reach USD 745.8 million in 2026. Future Market Insights projects the market will expand to USD 1.45 billion by 2036, reflecting a steady CAGR of 6.9% over the forecast period. This growth underscores the ongoing shift toward electric positioning systems that enhance...

NEWARK, DE | The HIV self-testing market stood at USD 240.1 million in 2025. According to Future Market Insights analysis, the market is estimated to expand to USD 272.8 million in 2026 and reach USD 971.8 million by 2036, reflecting a steady CAGR of 13.6% over the forecast period. This absolute dollar growth of USD 699.0 million underscores a major step forward in public...

NEWARK, DE | The global hyaluronic acid products market is estimated to be worth USD 9.43 billion in 2025 and is anticipated to reach USD 15.94 billion by 2035, expanding at a steady CAGR of 5.4% over the forecast period. This growth reflects rising adoption across cosmetic and medical applications, driven by the molecule's natural ability to trap...

According to a new report by UnivDatos, the PARP Inhibitors Market is projected to reach USD 13,835 million by 2032, expanding at a robust CAGR of 12.9% during the forecast period. PARP (Poly ADP-ribose Polymerase) inhibitors are a class of targeted cancer therapies that block the activity of PARP enzymes responsible for repairing single-strand DNA breaks. By inhibiting these enzymes, PARP...